On March 31, 2025, Jaguar Health, Inc. closed the transaction. The company issued $3.4 million aggregate principal amount of convertible promissory notes and warrants to purchase up to 622,584 shares of the Company?s common stock to selected institutional and accredited investors.
The transaction included participation from Lisa Conte, the Chief Executive Officer and President of the Company, invested approximately $50,000, Pravin Chaturvedi, the Chief Scientific Officer and the Chair of Scientific Advisory Board of the Company, invested approximately $20,000, Steven R. King, the Chief Sustainable Supply, Ethnobotanical Research, IP Officer and Secretary of the Company, invested approximately $20,000, Jonathan S. Wolin, the Chief of Staff, Chief Compliance Officer, and General Counsel of the Company, invested approximately $50,000, Carol Lizak, the Chief Financial Officer of the Company, invested approximately $30,000, James J. Bochnowski, a member of the Company?s board of directors, invested approximately $150,000, Jonathan B. Siegel, a member of the Company?s board of directors, invested approximately $50,000, John Micek III, a member of the Company?s board of directors, invested approximately $50,000, Niccolo Caderni invested approximately $20,000, Mark Johnson, an employee of the Company, invested approximately $25,000, David F. Sesin, the Chief Manufacturing Officer of the Company, invested approximately $50,000, Ian Wendt, the Chief Commercial Officer of the Company, invested approximately $20,000.
Jaguar Health, Inc. is a commercial-stage pharmaceuticals company. The Company is focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress. It operates through two segments: human health and animal health. The animal health segment is focused on developing and commercializing prescription and non-prescription products for companion and production animals. The human health segment is focused on developing and commercializing of human products and the ongoing commercialization of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with human immunodeficiency virus (HIV)/ acquired immunodeficiency syndrome (AIDS) on antiretroviral therapy. The Canalevia-CA1 is for the treatment of chemotherapy-induced diarrhea (CID) in dogs. Its subsidiary Napo Pharmaceuticals, Inc. focuses on developing and commercializing human prescription pharmaceuticals.
